3 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Adoptive engineered T cell Trials to Achieve Cancer Killing (ATTACK)
Date du début: 1 déc. 2012, Date de fin: 30 nov. 2017,
The aim of this research is to exploit technology for nucleic acid delivery through the clinical testing of adoptive engineered T cells to treat cancer. Recent innovative developments in cancer gene-immunotherapy have led to very encouraging early clinical results. However, the use of engineered T cells is a challenging and complex field with further development and more proof-of-principle trials ...
Voir le projet
16
Participants partenaires
TERMINÉ
Rational molecular Assessments and Innovative Drug Selection (RAIDS)
Date du début: 1 oct. 2012, Date de fin: 31 mars 2017,
Cervical cancer (CC) is the second most common cause of cancer deaths in women worldwide. The main objective of the RAIDs project is to use this model system which is accessible to repeat biopsies to learn how to stratify patients into targeted therapies. The patients’ tumors will be classified into molecular subtypes based on their molecular profile by use of high-throughput technologies (sequen ...
Voir le projet
19
Participants partenaires
TERMINÉ
Transposon-based, targeted ex vivo gene therapy to treat age-related macular degeneration (AMD) (TARGETAMD)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2016,
Age-related Macular Degeneration (AMD), a neurodegenerative disease of the retina, is a major cause of blindness in elderly people. Due to the aging population, AMD has been referred to as a “time bomb” in society. In the exudative form of AMD, high levels of vascular endothelial cell growth factor (VEGF) and low levels of pigment-epithelial derived factor (PEDF), an inhibitor of vascularization a ...
Voir le projet